Silence Therapeutics (SLN) Cash from Operations (2024 - 2026)
Silence Therapeutics (SLN) reported Cash from Operations of 15603000.0 for Q1 2026, down 26.76% on a YoY basis from 21304196.01 in Q1 2025, and up 9.89% sequentially from 17316000.0 in Q4 2025.
Silence Therapeutics (SLN) Cash from Operations (2024 - 2026) Analysis & Trends
Silence Therapeutics (SLN) has 3 years of Cash from Operations data on file, last reported at 15603000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 26.76% year-over-year to 15603000.0; the trailing twelve-month figure through Mar 2026 stood at 65594000.0 (up 7.36% YoY), and the FY2025 full-year result was 62300000.0, up 7.89% from the prior year.
- Cash from Operations improved to 15603000.0 in Q1 2026, from 17316000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 5409000.0 in Q2 2024 to a low of 27481000.0 in Q4 2024.
- A 3-year average of 16171444.44 and a median of 15603000.0 in 2026 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 57.5% in 2025, while the deepest fall reached 302.87% in 2025.
- Tracing SLN's Cash from Operations over 3 years: stood at 27481000.0 in 2024, then surged by 36.99% to 17316000.0 in 2025, then rose by 9.89% to 15603000.0 in 2026.
- Business Quant data shows SLN's Cash from Operations at 15603000.0 in Q1 2026, 17316000.0 in Q4 2025, and 10884000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Silence Therapeutics | 1.62 Bn | 1.49 Bn | 411,000.00 | -15.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.60 Mn |
| Mar 31, 2026 | -15.60 Mn |
| Dec 31, 2025 | -17.32 Mn |
| Dec 31, 2025 | -17.32 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Jun 30, 2025 | -21.79 Mn |
| Jun 30, 2025 | -21.79 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Dec 31, 2024 | -27.48 Mn |
| Dec 31, 2024 | -27.48 Mn |
| Sep 30, 2024 | -25.61 Mn |
| Sep 30, 2024 | -25.61 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Mar 31, 2024 | -9.14 Mn |
| Mar 31, 2024 | -9.14 Mn |